缺氧对大鼠肺组织肺血管sis原癌基因和PDGF-BB蛋白表达的影响

为了探讨血小板生长因子ＢＢ（ＰＤＧＦ－ＢＢ）在缺氧性肺血管结构重塑中作用,通过建立大鼠缺氧性肺血管重塑动物模型,运用原位杂交技术和免疫组织化学染色技术检测不同缺氧时期大鼠肺组织中原癌基因ｓｉｓｍＲＮＡ和ＰＤＧＦ－ＢＢ蛋白表达。结果：（１）随着缺氧时间的延长,肺动脉壁肌层增厚,管腔变窄;（２）正常对照组肺组织及肺血管壁ｃ－ｓｉｓｍＲＮＡ和ＰＤＧＦ－ＢＢ蛋白质均极少表达（＋）;（３）缺氧３天后,两者表达均增多（）;（４）缺氧７天后其表达达高峰并持续至１４天（～）;（５）缺氧２１天后,两者表达均降低,但仍高于正常对照组（）。提示：缺氧可以刺激大鼠肺组织ｓｉｓｍＲＮＡ和ＰＤＧＦ－ＢＢ蛋白表达,其在缺氧性肺血管结构重塑形成中可能具有重要作用。     

抗真菌蛋白Rs—AFPs基因在大肠杆菌中的表达

将抗真菌蛋白Ｒｓ－ＡＦＰ１和Ｒｓ－ＡＦＰ２全长ｃＤＮＡ插入表达质粒ｐＥＴ－２２ｂ／ＮｃｏＩ＋ＳａｃＩ位点,构建成融合蛋白表达载体ｐＲＡＦ１和ｐＲＡＦ２．将不含信号肽编码序列的Ｒｓ－ＡＦＰ１和Ｒｓ－ＡＦＰ２ｃＤＮＡ分别插入ｐＥＴ－２２ｂ／Ｎｃｏｌ＋Ｓａｃｌ和ｐＥＴ－２２ｂ／Ｎｄｅｌ＋ＳａｃＩ位点,构建成不含信号肽序列的融合蛋白表达载体ｐＲＡＦ３、ｐＲＡＦ４和非融合蛋白表达载体ｐＲＡＦ５和ｐＲＡＦ６．将构建的上述各种表达载体转化Ｅ．ｃｏｌｉＢＬ２１,挑菌落培养,ＩＰＴＧ诱导,使Ｒｓ－ＡＦＰｓ基因得到表达,并用体外抑菌试验检测表达产物的活性,结果表明,各种表达载体的表达产物均具有不同程度的抑菌活性,其中,ｐＲＡＦ３和ｐＲＡＦ４表达产物的抑菌活性较明显．     

肺活检材料的4种肿瘤标记物表达及与肺癌预后的关系

应用增殖细胞核抗原 （ＰＣＮＡ）、ｒａｓ－ Ｐ２１、Ｐ５３ 单克隆抗体和ＣｅｒｂＢ２ 多克隆抗体, 对７１ 例肺癌的纤支镜活检标本和１０ 例正常肺组织进行免疫组织化学染色研究。结果发现： １０ 例正常肺组织均为阴性表达。７１ 例肺癌中, 上述４ 种抗体的阳性表达率分别为： ７０４２％ 、８０２８％ 、５６３４％ 和８１６９％ 。除ＣｅｒｂＢ２ 与肺癌分型相关外, 均与肺癌分型、分化及ＴＮＭ 分期无关。但与预后均呈负相关。结果表明： 上述４ 种抗体是有效的、可作为判断肺癌预后的肿瘤标记物     

肺癌中抗酸菌L型感染与PCNA及癌基因蛋白表达关系的研究

用改良抗酸染色及免疫组化染色（Ｓ—Ｐ）法探讨抗酸菌Ｌ型感染、增殖细胞核抗原（ＰＣＮＡ）、Ｐ２１、ｃ－ｅｒｂＢ－２等癌基因蛋白表达在肺癌发生、发展中的作用及其相互关系。结果显示：（１）５０例肺癌中抗酸菌Ｌ型感染率为４２０％,伴抗酸菌Ｌ型感染者,ＰＣＮＡ指数显著增高;（２）５０例肺癌中Ｐ２１、ｃ－ｅｒｂＢ－２阳性表达率分别为４４０％和３４０％;且随肺癌分期的增加及淋巴结转移而显著增高。结果表明抗酸菌Ｌ型感染可能是肺癌的重要因素之一;Ｐ２１、ｃ－ｅｒｂＢ－２表达预示肺癌预后不良;抗酸菌Ｌ型感染和癌基因蛋白可能在肺癌的不同发展阶段起作用。     

缺氧性肺动脉高压大鼠肺组织中血小板源性生长因子和c—my…

本研究分析了大鼠肺组织中血小板源性生长因子Ａ链、Ｂ链和ｃ－ｍｙｃ原癌基因ｍＲＮＡ。正常肺组织可表达１．７ｋｂ的ＰＤＧＦ－ＡｍＲＮＡ和３．５ｋｂ的ＰＤＧＦ－ＢｍＲＮＡ,还有少量２．２ｋｂｃｍＲＮＡ．在缺氧过程中,ＰＤＧＦ－Ｂ链ｍＲＮＡ和ｃ－ｍｙｃｍＲＮＡ迅速增加,至缺氧１４ｄ时,分别为正常的３倍和５倍。而ＰＤＧＦ－ＡｍＲＮＡ在缺氧７ｄ时增高,而后又略有降低。结果表明：缺氧的肺组织局生成的ＰＤＧＦ激活     

乳腺癌HSV—1,HSV—2与c—erbB—2的免疫组化研究

采用免疫组织化学Ｓ－Ｐ法检测５２例手术切除乳腺癌组织ｃ－ｅｒｂＢ－２蛋白和ＨＳＶ－１、ＨＳＶ－２表达情况。结果发现癌组织中ｃ－ｅｒｂＢ－２阳性３４例（６５．４％）;ＨＳＶ－１阳性３８例（７３．１％）;ＨＳＶ－２阳性１５例（２８．８％）。癌旁组织３２例,阳性分别为３例（９．４％）;１２例（３７．５％）;２例（６．３％）。乳腺癌中ｃ－ｅｒｂＢ－２阳性率明显高于癌旁组织。乳腺癌及癌旁的ＨＳＶ－１阳性率明显高于ＨＳＶ－２,乳腺癌ｃ－ｅｒｂＢ－２阳性组中ＨＳＶ－１和ＨＳＶ－２的表达有显著差异,而在阴性组二者无差异,提示乳腺癌的发生可能和ＨＳＶ－１感染密切相关,ｃ－ｅｒｂＢ－２表达也可能和ＨＳＶ－１感染有关。     

乙型肝炎、肝硬变和肝癌中HBxAg的表达及其在肝癌发生中的作用

对３７９例良、恶性肝组织进行的免疫组织化学研究显示,３３％的慢性迁延性肝炎（６／１８）、７６％的慢性活动性肝炎（２６／３４）、９２％的肝硬变（５７／６２）和９７％的肝细胞性肝癌（ＨＣＣ）（５８／６０）中有ＨＢｘＡｇ表达,阳性率高于ＨＢｓＡｇ或ＨＢｃＡｇ。癌周肝中的ＨＢｘＡｇ阳性率显著高于非癌周肝。与其它２种ＨＢＶ抗原不同,ＨＢｘＡｇ表达在细胞类型上有较明显的选择性,在肝小多角细胞（ＳＰＬＣ）、小细胞性不典型增生（ＳＣＤ）及ＨＣＣ中较强。与ＩＧＦⅡ、ｃ－ｅｒｂＢ－２、ｃ－ｍｙｃ和ＥＧＦ－Ｒ表达进行的对照研究表明ＨＢｘＡｇ与ＩＧＦⅡ和ｃ－ｅｒｂＢ－２这２种ＨＣＣ发生相关基因的表达关系密切。ＰＣＮＡ染色结果显示ＨＢｘＡｇ阳性组织的细胞增殖活性显著高于ＨＢｘＡｇ阴性组织。我们的结果还表明ＨＢｘＡｇ表达与肝细胞不典型增生的发生和进展有关、提出ＨＢＶＸ基因可能通过其表达产物（ＨＢｘＡｇ）首先激活ＩＧＦⅡ、ｃ－ｅｒｂＢ－２基因,继而引起显著的ＳＰＬＣ增生和ＳＣＤ而参与ＨＣＣ发生的．     

缺氧性肺动脉高压大鼠肺组织中血小板源性生长因子和c－myc基因表达增强

本研究分析了大鼠肺组织中血小板源性生长因子Ａ链、Ｂ链（ＰＤＧＦ－Ａ,ＰＤＧＦ－Ｂ）和ｃ－ｍｙｃ原癌基因ｍＲＮＡ在正常和缺氧时的含量变化。正常肺组织可表达１．７ｋｂ的ＰＤＧＦ－ＡｍＲＮＡ和３．５ｋｂ的ＰＤＧＦ－ＢｍＲＮＡ,还有少量２．２ｋｂｃ－ｍｙｃｍＲＮＡ。在缺氧过程中,ＰＤＧＦ－Ｂ链ｍＲＮＡ和ｃ－ｍｙｃｍＲＮＡ迅速增加,至缺氧１４ｄ时,分别为正常的３倍和５倍。而ＰＤＧＦ－ＡｍＲＮＡ在缺氧７ｄ时增高,而后又略有降低。结果表明：缺氧的肺组织局部生成的ＰＤＧＦ激活了ｃ－ｍｙｃ原癌基因,这对于缺氧性肺动脉高压的形成具有重要作用。     

脑星形胶质瘤基因表达及其与临床病理的关系

采用原癌基因Ｂｃｌ－２、Ｐ２１及抑癌基因Ｐ５３、Ｒｂ蛋白４种抗体,用ＡＢＣ免疫组织化学方法对４０例脑星形胶质瘤组织作免疫组化染色．结果发现：Ｂｃｌ－２及Ｐ５３基因表达在Ⅰ～Ⅳ级胶质瘤中阳性率有显著性差异,而且染色强度也有明显差异．Ｐ２１、Ｒｂ基因表达在Ⅰ～Ⅳ级胶质瘤中呈上升趋势,但仅在Ⅰ～Ⅲ级、Ⅰ～Ⅳ级之间有明显差异．可以认为：Ｂｃｌ－２、Ｐ５３、Ｐ２１、Ｒｂ在胶质瘤的发生中发挥一定的作用,尤其是Ｂｃｌ－２、Ｐ５３基因,这些基因蛋白的表达与胶质瘤恶性程度有关．测定胶质瘤中的Ｂｃｌ－２、Ｐ５３、Ｐ２１、Ｒｂ蛋白对于胶质瘤的诊断、鉴别诊断以及判断肿瘤的恶性程度与预后均有一定意义．     

生长因子受体类癌基因的扩增与胃癌癌变的关系

用Ｓｏｕｔｈｅｒｎ杂交技术检查了３２例胃癌组织和４株胃癌细胞系中原癌基因ｍｅｔ、ｅｒｂＢ２、ＥＧＦＲ、ＡＫＴ－２、Ｒａｓ和ｍｙｃ的扩增,发现ｍｅｔ基因扩增６例,ＥＧＦＲ扩增１例、缺失２例,ＡＫＴ－２扩增２例,没有发现Ｒａｓ基因和ｍｙｃ基因的扩增．有癌基因异常的病例多为低分化、临床分期为Ⅲ、Ⅳ期的个体,提示癌基因扩增是肿瘤发展的晚期事件。     

Expression of ras oncogene p21 during human fetal development as determined by monoclonal antibodies RAP-5, Y13-259, and DWP

In this report we describe the expression of the ras proto-oncogene p21 protein in various tissues during normal fetal development. Conventional, formalin fixed and paraffin-embedded sections of normal organs were examined from fetuses ranging 9 to 42 weeks of gestation. Immunohistochemical localization of ras p21 was accomplished using the broadly reactive, mouse monoclonal antibodies RAP-5 and Y13-259. The monoclonal antibody DWP, which is specific for a mutated form of ras p21 having a valine/cysteine at amino acid position 12, was also used. Detectable expression of the p21 protein was seen at different time periods during fetal development depending on the tissue. The expression of ras p21 (as detected by RAP-5 and Y13-259) was noted in a wide range of cell types and tissues; intense immunostaining was noted in epithelial cells of the gastrointestinal tract, exocrine and endocrine pancreas, renal tubules and transitional urotheliem, as well as in other tissues. This immunostaining generally, but not invariably, corresponded with patterns previously reported in benign and/or malignant neoplasms of adult tissues. In most instances ras p21 expression, when present, occurred during periods of rapid growth in given organ systems. However, some actively proliferating fetal tissues such as thymus and spleen, failed to express detectable ras p21 suggesting that factors other than cell cycle may influence its expression. No reactivity with DWP was noted in any of the tissues, suggesting that the mutated forms detected by this monoclonal antibody are not expressed during normal human embryogenesis. These data show that there is regulated expression, and broad distribution of this gene product in normal developing human fetal tissue.     

c‐erbB‐2 and p53 expression in breast cancer fine needle aspirates

The aim of this study was to co‐evaluate c‐ erbB ‐2 and p53 protein expression in breast cancer fine needle aspirates (FNA) and to compare this with histological variables and the immunohistochemical phenotype of the tumours. Furthermore, we assessed the relationship of c‐ erbB ‐2 and p53 immunocytochemical expression to tumour prognostic factors. We examined 124 breast cancer FNAs and 79 matched surgical specimens using the avidin–biotin complex (ABC) and the alkaline phosphatase immunocytochemical techniques. C‐ erbB ‐2 immunopositivity was detected in 37.9% of the FNAs, while 31.7% were positive for p53. A statistically significant correlation was observed between p53 negativity and absence of c‐ erbB ‐2 immunostaining in the FNAs ( P =0.0007). Smears from infiltrating ductal carcinomas tended to be more frequently positive for p53 (36.7%) than those from lobular carcinomas (11.7%) ( P =0.054). In matched tumour tissues, c‐ erbB ‐2 was positive in 16.7% and p53 in 19% of cases. The immunocytochemical results for both c‐ erbB ‐2 and p53 were significantly correlated with the immunohistochemical results. There was no correlation between c‐ erbB ‐2 and p53 immunostaining, in both FNAs and tissues, and patients' menopausal status, tumour size, grade and lymph node status.     

Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis

Previous work from this laboratory demonstrated de novo synthesis of angiotensin (ANG) peptides by apoptotic pulmonary alveolar epithelial cells (AEC) and by lung myofibroblasts in vitro and in bleomycin-treated rats. To determine whether these same cell types also synthesize ANG peptides de novo within the fibrotic human lung in situ, we subjected paraffin sections of normal and fibrotic (idiopathic pulmonary fibrosis, IPF) human lung to immunohistochemistry (IHC) and in situ hybridization to detect ANG peptides and angiotensinogen (AGT) mRNA. These were analyzed both alone and in combination with cell-specific markers of AEC [monoclonal antibody (MAb) MNF-116] and myofibroblasts [alpha-smooth muscle actin (alpha-SMA) MAb] and an in situ DNA end labeling (ISEL) method to detect apoptosis. In normal human lung, IHC detected AGT protein in smooth muscle underlying normal bronchi and vessels, but not elsewhere. Real-time RT-PCR and Western blotting revealed that AGT mRNA and protein were 21-fold and 3.6-fold more abundant, respectively, in IPF lung biopsies relative to biopsies of normal human lung (both P < 0.05). In IPF lung, both AGT protein and mRNA were detected in AEC that double-labeled with MAb MNF-116 and with ISEL, suggesting AGT expression by apoptotic epithelia in situ. AGT protein and mRNA also colocalized to myofibroblast foci detected by alpha-SMA MAb, but AGT mRNA was not detected in smooth muscle. These data are consistent with earlier data from isolated human lung cells in vitro and bleomycin-induced rat lung fibrosis models, and they suggest that apoptotic AEC and myofibroblasts constitute key sources of locally derived ANG peptides in the IPF lung.     

Expression of bcl-2 protein in bronchoalveolar lavage cell populations from patients with idiopathic pulmonary fibrosis.

OBJECTIVE: To investigate changes in the expression of the antiapoptotic protein bcl-2 in bronchoalveolar lavage fluid (BALF) cell populations in patients with idiopathic pulmonary fibrosis (IPF). STUDY DESIGN: Ten patients with IPF underwent fiberoptic bronchoscopy and bronchoalveolar lavage (BAL) in the area of maximal radiographic shadowing (based on high-resolution computed tomography findings). Results were compared with those of 10 normal people in the control group. Cellular bcl-2 expression was identified using an immunoperoxidase staining method. RESULTS: A statistically significant (P < .001) increase in the expression of bcl-2 in BALF neutrophils and eosinophils was observed in patients with IPF as compared with controls. BAL macrophages exhibited only a slight (statistically insignificant) increase in bcl-2 expression in IPF patients. No bcl-2 expression was observed in BAL lymphocytes from IPF patients in contrast to the control group. CONCLUSION: The overexpression of bcl-2 on BALF neutrophils and eosinophils, cells that characterize the special cellular profile of alveolitis in IPF, could be one of the pathophysiologic mechanisms of this disease.     

Cell type-specific expressions of c-ras gene products in the normal rat

Expression of proteins encoded by the ras proto-oncogenes was examined immunohistochemically in formalin-fixed, paraffin-embedded tissues of the normal rat using anti-ras p21 antibodies generated against synthetic peptides. Cell type specific expressions of ras gene products were detected in distal tubules of kidney, megakaryocytes in spleen, neural cells in cerebrum, Purkinje cells in cerebellum, cells lining the pulmonary alveoli and cells in the epithelium of intestinal villi. Region specific expressions of the ras proteins were observed in spleen and thymus, where the ras proteins were detected in splenic nodules including germinal centers and thymic medulla, respectively. These findings suggest that the c-ras gene products in normal rat organs are expressed in specific cell-types within a tissue and may be associated with degree of cellular differentiation.     

Abundant expression of ras proteins in Aplysia neurons

We have cloned a DNA fragment from the marine mollusc Aplysia californica, which contains sequences homologous to mammalian ras genes, by screening a genomic library with a viral Ha-ras oncogene probe under conditions of low stringency hybridization. Nucleotide sequencing revealed a putative exon that encodes amino acids sharing 68% homology with residues 5 to 54 of mammalian p21ras polypeptides, and which therefore is likely to encode a ras-like Aplysia protein. The cloned locus, designated Apl-ras, is distinct from the Aplysia rho (ras-homologue) gene and appears to be more closely related to mammalian ras. We used a panel of monoclonal antibodies raised against v-Ha-ras p21 to precipitate an Mr 21,000 protein from extracts of Aplysia nervous tissue, ovotestis, and, to a much lesser degree, buccal muscle. Fluorescence immunocytochemistry revealed that ras-like protein is most abundant in neuronal cell bodies and axon processes, with staining most prominent at plasma membranes. Much less was present in other tissues. The prominence of ras protein in neurons, which are terminally differentiated and non-proliferating, indicates that the control of cell division is not the sole function of this proto-oncogene. The large identified neurons of Aplysia offer the opportunity to examine how ras protein might function in mature nerve cells.     

Immunohistochemical analysis of normal and mutated ras oncogene p21 expression in human pulmonary and pleural neoplasms

In this study we examined 214 cases of primary human pulmonary neoplasms for the expression of a mutated form of the ras oncogene p21 product, recognized by the monoclonal antibody (MCA) DWP. Adjacent serial sections from these same cases had previously been used to demonstrate the frequency of ras p21 expression using the broadly reactive anti-ras p21 MCA RAP-5. Confirmation of the increased expression of p21 was accomplished using MCA Y13-259. The use of adjacent tissue sections from these cases allows the direct comparison of the expression of the mutated and non-mutated forms of ras p21. If reactivity with DWP would prove to be significantly more restrictive than that of the "pan" ras MCAs, RAP-5 and Y13-259, it would lend support to the possibility that DWP (and similar MCAs which detect other specific mutations) could be used to define subsets of these neoplasms based on their specific ras p21 phenotype. Since one would anticipate that the valine/cysteine substitution at position 12 of the ras p21 would occur at only low frequencies in human tumors, our results with DWP are consistent with this hypothesis. As previously reported, RAP-5 reacted with a high proportion of lung tumors (100/214 or 47%). In this report, we demonstrate the selective expression of the mutation recognized by the MCA DWP in only 5% of these same tumors (13/214), and that the expression of this mutated form is not restricted to any of the conventional histological subclasses of pulmonary neoplasms.